Post COVID-19 symptoms are common, also among young adults in the general population.

Publication date: Jul 12, 2023

Post coronavirus disease-19 (post COVID-19) is mainly studied in clinical populations and less is known about post COVID-19 in a young general population. The aim of the study is to investigate the prevalence and symptoms of post COVID-19 and its potential risk factors in young adults. Participants from the Swedish population-based birth cohort BAMSE were included (n = 2022, mean age 26. 5 years). Post COVID-19 was assessed through a questionnaire and defined as symptoms after confirmed COVID-19 (registry-based or self-reported positive test) lasting for ≥ 2 months. In total, 681 participants had had confirmed COVID-19. Among them, 112 (16. 5%) fulfilled the definition of post COVID-19 (17. 8% in females, 14. 5% in males, p = 0. 26). The most common post COVID-19 symptoms were altered smell and taste (68. 8%), dyspnea (33. 7%) and fatigue (30. 4%). Overall, no major risk factors for post COVID-19 were identified except for being bedbound during COVID-19. However, asthma and rhinitis were associated with the post COVID-19 symptom dyspnea, migraine with altered smell and taste, and lower self-rated health with fatigue. In conclusion, post COVID-19 symptoms are common, also among young adults in the general population. Although not life-threatening, it could have a considerable impact on public health due to the high prevalence and long-term symptoms.

Open Access PDF

Concepts Keywords
Coronavirus Adults
Dyspnea Based
Swedish Common
Taste Confirmed


Type Source Name
disease MESH COVID-19
disease VO population
disease MESH asthma
pathway KEGG Asthma
disease MESH rhinitis
disease IDO symptom
disease MESH migraine
disease MESH Long Covid
drug DRUGBANK Coenzyme M
disease MESH virus disease
disease MESH infection
disease MESH death
disease MESH sequelae
disease IDO history
disease IDO acute infection
disease MESH cardiovascular disease
disease MESH obesity
disease VO vaccination
disease MESH lifestyle
disease MESH chronic diseases
disease VO dose
disease MESH overweight
disease MESH ADHD
disease MESH chronic bronchitis
disease MESH symptom clusters
disease MESH inflammation
disease MESH morbidities
disease IDO susceptibility
disease VO time
disease IDO blood
disease MESH tachycardia
disease MESH cognitive impairment
disease MESH chest pain
disease MESH joint pain
disease MESH sleep disorders
disease MESH pneumonia
disease MESH bronchitis
drug DRUGBANK Nitrogen
disease VO USA
disease MESH Allergy
disease MESH Smell dysfunction
disease VO unvaccinated
disease VO vaccinated
disease MESH post infectious disorders
disease IDO cell
drug DRUGBANK Medical air
drug DRUGBANK Etoperidone
pathway REACTOME Reproduction

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *